BioCardia (NASDAQ:BCDA) Director Acquires $498,000.00 in Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer acquired 398,400 shares of BioCardia stock in a transaction dated Friday, September 19th. The stock was purchased at an average price of $1.25 per share, with a total value of $498,000.00. Following the completion of the purchase, the director owned 591,054 shares of the company’s stock, valued at approximately $738,817.50. The trade was a 206.80% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioCardia Stock Down 4.7%

Shares of NASDAQ BCDA opened at $1.41 on Friday. The business’s 50 day moving average price is $1.92 and its 200 day moving average price is $2.15. The firm has a market cap of $8.19 million, a P/E ratio of -0.76 and a beta of 0.85. BioCardia, Inc. has a 52 week low of $1.00 and a 52 week high of $3.20.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. As a group, research analysts expect that BioCardia, Inc. will post -3.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BCDA shares. Zacks Research raised shares of BioCardia to a “hold” rating in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, BioCardia presently has a consensus rating of “Buy” and a consensus target price of $25.00.

Institutional Trading of BioCardia

A number of institutional investors and hedge funds have recently modified their holdings of BCDA. Cetera Investment Advisers purchased a new position in shares of BioCardia in the second quarter valued at approximately $40,000. CM Management LLC raised its stake in BioCardia by 200.0% in the 1st quarter. CM Management LLC now owns 75,000 shares of the company’s stock valued at $190,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Brown Advisory Inc. purchased a new position in BioCardia in the 1st quarter valued at $90,000. Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.